TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02928393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
Study: NCT00631722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quatiapine Fumarate
Description: 600-750mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 12-20mg/day
Study: NCT00575822

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NDO Full-thickness Plicator
Description: A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
Study: NCT02615717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: comparison of treatment versus control

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: comparison of treatment versus control
Study: NCT03619148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flow Humidified Nasal Oxygen
Description: High-Flow Humidified Nasal Oxygen

Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flow Humidified Nasal Oxygen
Description: High-Flow Humidified Nasal Oxygen
Study: NCT01617096

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ring
Description: Vaginal ring containing no drug substance
Study: NCT02472639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostom-i Alert Sensor
Description: Wear the Ostom-i Alert Sensor

Intervention type: OTHER
Group type: OTHER
Intervention: No Ostom-i Alert Sensor
Description: Patient will not use device
Study: NCT01567527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular (IM) Depot Aripiprazole
Description: Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular (IM) Depot Placebo
Description: Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
Study: NCT01011413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600mg
Description: 3 x EFV 200 milligram (mg) tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400mg
Description: 2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
Study: NCT03655977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI scan instead of only MRI
Description: Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI scan instead of only MRI
Description: Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
Study: NCT03255980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xonrid® gel
Description: Water based gel for the management of toxicity skin symptoms induced by Radiotherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xonrid® gel
Description: Water based gel for the management of toxicity skin symptoms induced by Radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
Study: NCT01847950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short-chain fructo-oligosaccharides
Description: Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT04345822

Intervention type: PROCEDURE
Intervention: Decompression surgery
Description: The surgeries aim to relieve the myelopathy from cord compression

Intervention type: PROCEDURE
Intervention: Decompression surgery
Description: The surgeries aim to relieve the myelopathy from cord compression
Study: NCT02123823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 10mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: at recommended dose as per Phase I data

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Fixed dose at 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Human monoclonal antibody at recommended dose as per Phase I data

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Fixed dose at 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Fixed dose at 25mg
Study: NCT03859700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DBV712 250 mcg
Description: DBV712 250 mcg, once daily
Study: NCT04116320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.
Study: NCT03566667

Intervention type: DRUG
Group type: OTHER
Intervention: Standard care
Description: Standard care
Study: NCT02532192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours.
Study: NCT04116320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Poly-ICLC is a TLR3 agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Poly-ICLC is a TLR3 agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care PD-1 Therapy
Description: PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care PD-1 Therapy
Description: PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.
Study: NCT01892527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ197)
Description: Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
Study: NCT01492647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 1.2%
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 10229570-AAA 3.6%
Description: One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
Study: NCT02532192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 mg by mouth twice daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 100 mg by mouth daily for 10 days.
Study: NCT02488057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Active comparator. See arm descriptions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: Active comparator. See arm descriptions.
Study: NCT01492647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Color-matched vehicle containing 0 mg of JNJ 10229570-AAA
Description: One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
Study: NCT02488057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: Active comparator. See arm descriptions.
Study: NCT03206749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
Study: NCT03953586

Intervention type: DIAGNOSTIC_TEST
Intervention: Bubble suction test and tubal peristalsis
Description: Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)

Intervention type: DIAGNOSTIC_TEST
Intervention: Bubble suction test and tubal peristalsis
Description: Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
Study: NCT03567291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6, 9, and 12 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6, 9, and 12 mg oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04942353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Rehabilitation.
Description: Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
Study: NCT03083730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow band UVB treatment (NB-UVB)
Description: NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
Study: NCT00226044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole rectally 1mg/kg
Description: A single dose of 1 mg/kg rectally administered omeprazole.
Study: NCT03206749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to VX-150 and HB/APAP for 2 days.
Study: NCT01363817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024
Study: NCT03739944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomic radical hysterectomy
Description: Laparotomic radical hysterectomy for patients without fertility requirement
Study: NCT03739944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomic radical trachelectomy
Description: Laparotomic radical hysterectomy for patients with fertility requirement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic radical hysterectomy
Description: Laparoscopic radical hysterectomy for patients without fertility requirement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic radical trachelectomy
Description: Laparoscopic radical hysterectomy for patients with fertility requirement
Study: NCT01790438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin NPH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antihyperglycemic Medications (OAM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antihyperglycemic Medications (OAM)
Study: NCT03855917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400mg [Sovaldi]
Description: Four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (300mg/120mg)
Description: Four weeks.
Study: NCT00716404

Intervention type: DEVICE
Intervention: Targeted Renal Therapy
Description: Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
Study: NCT03117049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study: NCT05629104

Intervention type: OTHER
Intervention: There is no intervention since it is an observational study patients are treated according to clinical praxis
Description: No intervention

Intervention type: OTHER
Intervention: There is no intervention since it is an observational study patients are treated according to clinical praxis
Description: No intervention
Study: NCT01363817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT00757705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
Study: NCT02028416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG-fresenius
Description: we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-fresenius
Description: we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days
Study: NCT01567319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skin Prick Test
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - Atopic Subjects
Description: Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - No Atopic Subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study: NCT03196557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prenisolone
Description: Specified dose on specified days
Study: NCT04148677

Intervention type: DIETARY_SUPPLEMENT
Intervention: Protoves M1®
Description: A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
Study: NCT03598634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of riboflavin for epi-off cross-linking
Description: riboflavin 0.1% in 20% dextran solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of riboflavin for epi-off cross-linking
Description: riboflavin 0.1% in 20% dextran solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of riboflavin for epi-on cross-linking
Description: riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of riboflavin for epi-on cross-linking
Description: riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
Study: NCT01830075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations
Description: The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
Study: NCT02337348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Preintervention imaging

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography
Description: Conventional coronary intervention

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Conventional coronary intervention
Study: NCT03117049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Study: NCT03172546

Intervention type: GENETIC
Intervention: PK-PD genetic polymorphisms
Description: PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment

Intervention type: GENETIC
Intervention: PK-PD genetic polymorphisms
Description: PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment